This study explores a novel therapeutic strategy for relapsed/refractory (R/R) Burkitt lymphoma (BL) by integrating autologous hematopoietic stem cell transplantation (ASCT) with tandem anti-CD19/CD22 chimeric antigen receptor (CAR) T cell therapy. A 20-year-old Asian male with refractory BL, whose lymphoma had not responded to multiple chemoimmunotherapy regimens, received myeloablative ASCT followed three days later by infusion of a novel third-generation CAR T cells engineered with CD28 and CD3ζ signaling domains, along with a TLR2 costimulatory domain. This resulted in sustained complete remission at the 306-day follow-up, without experiencing any severe complications. This case suggests that combining myeloablative ASCT with tandem anti-CD19/CD22 CAR T cell therapy could be an effective approach for R/R BL, warranting further clinical validation.
Keywords: CAR T-cell therapy; CD19/CD22 dual target; autologous hematopoietic stem cell transplantation; immunotherapy; relapsed/refractory Burkitt lymphoma.
Copyright © 2024 Luo, Chen, Qin, Weinkove, Zhao, Ye, Chen, Tang, Liu, Huang, Shi, Yuan, Tan, Qin, Tang, Li and Zheng.